GC
BIIB icon

Gruss & Co’s Biogen BIIB Stock Holding History

Gruss & Co’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-4,500
Closed -$1.31M – 31
2018
Q2 		$1.31M Hold
4,500
– – 1.33% 19
2018
Q1 		$1.23M Sell
4,500
-5,000
-53% -$1.55M 1.25% 22
2017
Q4 		$3.03M Buy
9,500
+500
+6% +$160K 2.96% 13
2017
Q3 		$2.82M Buy
9,000
+5,000
+125% +$1.48M 3.18% 11
2017
Q2 		$1.08M Hold
4,000
– – 1.23% 17
2017
Q1 		$1.09M Buy
4,000
+750
+23% +$212K 1.1% 23
2016
Q4 		$922K Buy
3,250
+250
+8% +$74.1K 1.01% 21
2016
Q3 		$939K Buy
3,000
+1,000
+50% +$296K 1.17% 20
2016
Q2 		$484K Hold
2,000
– – 0.58% 28
2016
Q1 		$521K Buy
+2,000
New +$528K 0.72% 28

Other funds holding BIIB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Gruss & Co's BIIB Position: Q3 2018 in Review

Gruss & Co sold out of Biogen (BIIB) in Q3 2018, closing a stake of 4,500 shares — an estimated $1.31M sold.

Gruss & Co first reported a position in BIIB in Q1 2016 and held it in 10 quarters. The position peaked at $3.03M in Q4 2017. 1,146 funds tracked by Wall St. Rank hold BIIB as of Q3 2018.

  • Gruss & Co reported no remaining Biogen position as of Q3 2018 after selling out during the quarter.
  • Gruss & Co sold 4,500 Biogen shares in Q3 2018, an estimated $1.31M.
  • Gruss & Co first reported a position in Biogen in Q1 2016 and held it in 10 quarters.
  • Gruss & Co's Biogen position peaked at $3.03M in Q4 2017.
  • 1,146 funds tracked by Wall St. Rank held Biogen as of Q3 2018.

Based on Gruss & Co's 13F filing for Q3 2018, filed 7 Nov 2018.